[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:polycythemia-vera":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":134,"states":139},"Polycythemia Vera",20,18,[8,16,23,30,36,41,47,53,60,66,72,78,84,90,96,102,108,114,120,127],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07429266","A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)",[12],"Phase 3","RECRUITING","2026-08-26T02:16:18.872924Z","2026-05-13T02:55:06.703153Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04644211","Ruxolitinib in Thrombocythemia and Polycythemia Vera",[20],"Phase 2","2026-08-26T02:15:24.145250Z","2026-05-05T02:43:27.955137Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT07469891","A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms",[27],"Phase 1","2026-08-26T02:16:06.684983Z","2026-05-05T02:43:27.656131Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT06093672","Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera",[12],"2026-08-26T02:17:02.694423Z","2026-05-05T02:35:31.754021Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":14,"content_modified":40},"NCT06351631","A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)",[12],"2026-05-05T02:43:27.946262Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT06313593","A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms",[27],"2026-08-03T03:34:20.548203Z","2026-05-05T02:43:27.444739Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT07441694","Study of INCA036978 in Participants With Myeloproliferative Neoplasms",[27],"2026-08-26T02:16:20.336282Z","2026-05-05T02:43:27.275822Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":58,"content_modified":59},"NCT05123365","An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms",[57],"Phase 1\u002FPhase 2","2026-08-26T02:15:11.740957Z","2026-05-05T02:43:26.953012Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT06541249","MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial",[20],"2026-08-26T02:16:04.914942Z","2026-04-29T02:57:57.065431Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT04282187","Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated\u002FBlast Phase Myeloproliferative Neoplasms",[20],"2026-08-26T02:17:39.048487Z","2026-05-05T02:43:29.738874Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT05031897","Two Step Haplo With Radiation Conditioning",[20],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:29.158573Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT06063486","Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms",[20],"2026-08-26T02:16:17.877565Z","2026-05-05T02:43:29.075022Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT06661915","A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)",[20],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:28.360451Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT06523556","Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm\u002FMyelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia",[57],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.949132Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT06291987","Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation",[27],"2026-08-26T02:15:21.365312Z","2026-05-05T02:43:27.513961Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT06218628","Pacritinib w\u002F Talazoparib in Pts w\u002F Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition",[27],"2026-08-26T02:16:24.135291Z","2026-05-05T02:35:31.622551Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT07203768","A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes",[],"2026-08-26T02:18:45.196599Z","2026-05-13T02:55:06.671760Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT07362225","MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)",[],"2026-08-26T02:15:36.077529Z","2026-05-13T02:55:06.699757Z",{"nct_id":121,"title":122,"phases":123,"status":124,"updated_at":125,"content_modified":126},"NCT07349134","WELL-MPN: A Digital Lifestyle App for Patients With MPNs",[],"NOT_YET_RECRUITING","2026-08-26T02:17:32.059863Z","2026-05-05T02:43:28.705774Z",{"nct_id":128,"title":129,"phases":130,"status":131,"updated_at":132,"content_modified":133},"NCT06985147","A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T02:51:12.602181Z","2026-05-05T02:43:26.985580Z",[135],{"biomarker":136,"count":137,"slug":138},"JAK2 Gene",4,"jak2-gene",[140,144,147,150,154,158,161,164,167,170,173,176,180,183,186,189],{"state":141,"count":142,"slug":143},"California",7,"california",{"state":145,"count":142,"slug":146},"New York","new-york",{"state":148,"count":142,"slug":149},"Ohio","ohio",{"state":151,"count":152,"slug":153},"Florida",6,"florida",{"state":155,"count":156,"slug":157},"North Carolina",5,"north-carolina",{"state":159,"count":156,"slug":160},"Pennsylvania","pennsylvania",{"state":162,"count":156,"slug":163},"Texas","texas",{"state":165,"count":137,"slug":166},"Illinois","illinois",{"state":168,"count":137,"slug":169},"Michigan","michigan",{"state":171,"count":137,"slug":172},"Oregon","oregon",{"state":174,"count":137,"slug":175},"Tennessee","tennessee",{"state":177,"count":178,"slug":179},"Alabama",3,"alabama",{"state":181,"count":178,"slug":182},"Maryland","maryland",{"state":184,"count":178,"slug":185},"Massachusetts","massachusetts",{"state":187,"count":178,"slug":188},"Utah","utah",{"state":190,"count":178,"slug":191},"Washington","washington"]